How do you diagnose ALL?
Q. I’m currently doing a research report on acute lymphoblastic leukaemia and I was wondering, are cytomorphology and cytochemistry important in the diagnosis of ALL? (more…)
Q. I’m currently doing a research report on acute lymphoblastic leukaemia and I was wondering, are cytomorphology and cytochemistry important in the diagnosis of ALL? (more…)
Q. Can you write a post about antiphospholipid syndrome? I could not find good source which explains its pathophysiology and laboratory results
A. First, before we get into the antiphospholipid syndrome, we need to talk about antiphospholipid antibodies. As you might expect from their name, antiphospholipid antibodies are autoantibodies in the patient’s plasma that are directed against various phospholipids (there are lots of phospholipid surfaces in the body – including the phospholipid surface upon which the coagulation factors interact). There are a bunch of different types of antiphospholipid antibodies, including anticardiolipin antibodies, anti-glycoprotein antibodies, and the so-called lupus anticoagulants (which were discovered in patients with lupus).
In addition to binding to various phospholipid surfaces in the body, these autoantibodies also just happen to bind to the phospholipid part of the PTT reagent (and sometimes, the PT reagent). Then there’s not enough usable reagent in the test tube, and the patient’s specimen doesn’t clot! The coagulation tests are therefore falsely prolonged.
Antiphospholipid antibodies are sometimes called “inhibitors” because they appear to inhibit coagulation in the test tube. But here’s a weird thing: in the body, they can be associated with thrombosis!
You may be asking yourself: how do you get these antiphospholipid antibodies? And are they dangerous?
It turns out there are different answers for different patients. Children, for example, sometimes develop antiphospholipid antibodies after an infection. In this setting, the risk of thrombosis is only slightly increased; it’s usually not a big deal clinically. Adults sometimes develop antiphospholipid antibodies as part of an autoimmune disorder like lupus (in fact, antiphospholipid antibodies – in whatever clinical setting – are often called “lupus inhibitors” because of this association). In these patients, the risk of thrombosis is moderately increased. Finally, elderly adults may develop antiphospholipid antibodies in association with drugs. This is virtually always a harmless event with no increased risk of thrombosis.
Okay, so here’s where we get to the antiphospholipid antibody syndrome part. This term is used when a patient with an antiphospholipid antibody has thromboses or pregnancy-related complications (like recurrent miscarriage, pre-term labor, or pre-eclampsia). This syndrome is a serious thing. In a small number of patients, the thromboses can be widespread, leading to multi-organ system damage and death. The term is reserved for patients who are symptomatic; you wouldn’t use the term in patients who have an antiphospholipid antibody but no symptoms.
So what would you do if you think your patient might have an antiphospholipid antibody? Well, you’d need to confirm this suspicion with laboratory tests. First, order a PTT (in fact, that’s how a lot of these patients get picked up – they present with an abnormally prolonged PTT in the face of clinical evidence of thrombosis).
Then, order up a mixing study. Remember what a mixing study is? You do this test when you have a patient with a prolonged PTT and you want to know why. It’s performed by taking the patient’s (probably abnormal) plasma and mixing it with some pooled (normal) plasma – then running the PTT on this new mixed sample.
If the new PTT value is within the normal range (if it “corrects”), then you know the pooled human plasma must have supplied something to the patient’s plasma to make it clot normally. The “something” is usually a coagulation factor that the patient is missing.
If the new PTT value is still abnormal (if it’s still prolonged, and doesn’t “correct”), then you know that even though you added a bunch of normal plasma to the mix, the patient’s plasma still couldn’t clot normally. There must be some other problem with the patient’s plasma. The “other problem” is usually an inhibitor.
One caveat: some antiphospholipid antibodies do not prolong the PTT. It all depends on the particular PTT reagent your lab is using (some reagents are just more easily swayed by the antiphospholipid antibodies). So if you really feel your patient may have an antiphospholipid antibody, you shouldn’t stop investigating that possibility just because the PTT comes back normal! There are plenty of fancy lab tests that can be done to detect antiphospholipid antibodies. Just call your friendly neighborhood pathologist and see what he/she has to offer.
Q. In liver cirrhosis, why is the PTT not elevated? In all of my review books, it says the PT is used as one of the ways to evaluate liver function. (more…)
Okay, so this post is more about being a student than it is about the study of pathology. Bear with me: there is important information here! (more…)
Today’s post, authored by a very smart guest cytogeneticist, nicely describes array-based comparative genomic hybridization, a very cool DNA test that gives us a way to detect genetic abnormalities that are too small to be seen under the microscope. (more…)
Q. I have been trying to figure out the two basic thyroid lab tests, TSH and T4. If you have a high TSH and a low T4 does that mean that the pituitary gland is going crazy to reach homeostasis but the thyroid is not responding? And inversely, if the T4 is high and the TSH is low does that mean for some reason the thyroid is working overtime due to a disease like Graves disease, and the pituitary is trying to compensate by not producing TSH?
A. Yes! That’s exactly right. When the two (TSH and T4) are opposite of each other – high T4/low TSH or low T4/high TSH – that means that the problem is intrinsic to the thyroid gland (Graves disease or Hashimoto thyroiditis, for example) and the pituitary is trying to control the thyroid by producing more or less TSH. Those are the most common types of thyroid disease – those that are intrinsic, or primary to the thyroid gland itself.
On the other hand, if both TSH and T4 are either low or high – high T4/high TSH or low T4/low TSH – that means that the process is being driven by TSH. Either there’s a pituitary adenoma making a ton of TSH, or the pituitary is not working well for whatever reason (it’s been radiated, or has undergone necrosis) and it’s not making enough TSH.
Image credit: akay (http://www.flickr.com/photos/akay/245002004/), under cc license.
We were talking about developmental pathology the other day in class – trisomies, sex chromosome numerical abnormalities, microdeletion syndromes etc. – and the term “uniparental disomy” came up. (more…)
Pathology Student is back after a nice long holiday hiatus. We will begin 2010 with a new series of real live questions from real live students. It is important to hear other students’ questions (and answers) because 1) you will probably learn or clarify something, and 2) it will hopefully encourage you to ask your own questions. So, without further ado, here are some questions and answers about female reproductive system pathology.
Q. In endometriosis, is the glandular tissue found outside of the uterus and not associated with it at all other than being of similar cellular makeup? In other words, is it essentially extra-uterine menses?
A. Endometriosis is extra-uterine endometrial tissue, not associated with the stuff inside the uterus at all – other than it is under the same hormonal control, so when the endometrial tissue inside the uterus undergoes cyclic changes, so will the endometrial tissue (endometriosis) outside the uterus.
Q. Is nulliparity a risk factor in endometrial hyperplasia?
A. Yes, actually, it is, although our textbook [Robbins Basic Pathology] doesn’t mention it. It falls into the category of things-that-increase-estrogen-exposure, so it’s a risk factor for any of the tumors related to estrogen excess.
Q. The risk factors for endometrial hyperplasia include exogenous hormone use. Is this the same thing as estrogen replacement therapy?
A. In this setting, yes, they are the same thing. If you want to be complete about it, there are other kinds of exogenous hormones – like birth control pills – but when we’re talking about endometrial hyperplasia, the exogenous hormomes referred to are estrogen replacement therapy (birth control pills don’t have that effect on the endometrium).
Q. It seems like too much estrogen causes a bunch of issues. Do many of these pathologies arise simultaneously in the presence of excess estrogen?
A. No, not usually. The chances of any one tumor or lesion arising are relatively small (even though the risk is increased compared to the setting of normal estrogen), so the chances of two developing at the same time are very small.
Q. Can you give an example of what metrorrhagia is and when it might take place?
A. Metrorrhagia means there is bleeding outside the normal period time, for example: abnormally-timed bleeding during menopause, or bleeding from an intra-uterine tumor (which would not follow normal hormonal stimuli).
Q. Could a teratoma be an ectopic pregnancy?
A. No – a teratoma is a neoplasm; it is monoclonal. It arises from a germ cell that has gone bad and decided to develop into all three germ cell layers. The cells may grow to look like normal tissues, but they’re not under any embryologic organization or control (they just grow haphazardly). A pregnancy, whether it is intrauterine or extrauterine, is not monoclonal; the tissues are growing in response to embryologic signals, and if left alone, will organize into a human.
Q. What is peau d’orange?
A. Peau d’orange (French for “skin of the orange”Â) happens when you have a breast cancer that has infiltrated the lymphatics of the breast skin, making the skin edematous and orange-peel-looking. This change often happens in inflammatory breast cancer (so-named because the skin can look inflamed), in which the tumor preferentially involves lymphatics.
Q. My 28 year old friend was just diagnosed with multiple sclerosis. What can he expect regarding prognosis?
A. MS is a demyelinating disease that is thought to be autoimmune in nature. It is not easy to predict an exact prognosis for an individual patient, but I think you can boil it down to the fact that while a small number of people with MS become unable to write, speak, or walk, the vast majority of patients are mildly affected by their disease. Let’s look at this in a little more detail.
Subtypes
There are several subtypes of MS, each with different symptoms and prognoses. Note that the frequencies of the different subtypes listed in different sources may not be comparable, because some sources refer to the frequency at diagnosis, while others refer to an overall frequency. It would be useful to know which subtype your friend fits into, because that may help determine his prognosis.
1. Benign MS
People with this type of MS have only rare attacks, and are minimally disabled 10 years after their diagnosis (therefore, you can’t make this diagnosis until 10 years have elapsed!).
2. Relapsing-Remitting
People with this type of MS attacks followed by partial or complete recovery periods free of disease progression. This is the most common type at diagnosis – but some patients move into one of the other types later on.
2. Primary-Progressive
People with this type of MS experience a slow but nearly continuous worsening of their disease from the onset, with no distinct relapses or remissions. This is an uncommon subtype.
3. Secondary-Progressive
People with this type of MS experience an initial period of relapsing-remitting MS, followed by a steadily worsening disease course. Many people with relapsing-remitting MS developed this form later on – but that was before new drugs for MS were introduced. This subtype may be less frequent now.
4. Progressive-Relapsing
People with this type of MS experience a steadily worsening disease from the onset but also have relapses, with or without recovery. In contrast to relapsing-remitting MS, the periods between relapses are characterized by continuing disease progression. This is an uncommon subtype.
Factors influencing prognosis
1. Factors associated with a better prognosis:
2. Factors associated with a less favorable prognosis:
All that being said.
It’s going to be hard to tell with a lot of certainty at this point what your friend’s prognosis is, because the diagnosis is new. Once he has had the disease a few years, then it will be important to see how it has progressed (or not progressed), because one of the more important predictors of one’s future MS course is one’s past MS course.
Here are some good web resources for learning more about MS:
1. The NIH
http://www.ninds.nih.gov/disorders/multiple_sclerosis/multiple_sclerosis.htm
2. The National Multiple Sclerosis Society
http://www.nationalmssociety.org/index.aspx
3. The University of California – San Francisco Multiple Sclerosis Center
http://www.ucsf.edu/msc/faq.htm#beyond
4. The Multiple Sclerosis International Federation
http://www.msif.org/en/about_ms/types_of_ms.html
The illustration above is from Joseph Babinski’s 1885 thesis, “Etude anatomique et clinique de la sclérose en plaques.”
Here are some real student questions about myeloproliferative disorders. You should always ask questions when you don’t understand something – preferably in lecture. (more…)
Recent Comments